Skye Bioscience, Inc. Common Stock (SKYE) - Total Assets
Based on the latest financial reports, Skye Bioscience, Inc. Common Stock (SKYE) holds total assets worth $11.03 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Skye Bioscience, Inc. Common Stock - Total Assets Trend (2012–2025)
This chart illustrates how Skye Bioscience, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data. Also see SKYE market cap for the company's overall valuation and market capitalisation.
Skye Bioscience, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2025)
Skye Bioscience, Inc. Common Stock's total assets of $11.03 Million consist of 95.7% current assets and 4.3% non-current assets. Review debt load of Skye Bioscience, Inc. Common Stock to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.8% |
| Accounts Receivable | $10.47K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Skye Bioscience, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See SKYE stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Skye Bioscience, Inc. Common Stock's current assets represent 95.7% of total assets in 2025, an increase from 89.4% in 2012.
- Cash Position: Cash and equivalents constituted 20.8% of total assets in 2025, down from 61.6% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 0.0% of total assets.
Skye Bioscience, Inc. Common Stock Competitors by Total Assets
Key competitors of Skye Bioscience, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Skye Bioscience, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.95 | 6.09 | 7.61 |
| Quick Ratio | 0.95 | 6.09 | 7.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-572.22K | $42.27 Million | $9.93 Million |
Skye Bioscience, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between Skye Bioscience, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.96 |
| Latest Market Cap to Assets Ratio | 0.31 |
| Asset Growth Rate (YoY) | -61.1% |
| Total Assets | $28.31 Million |
| Market Capitalization | $8.81 Million USD |
Valuation Analysis
Below Book Valuation: The market values Skye Bioscience, Inc. Common Stock's assets below their book value (0.31x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Skye Bioscience, Inc. Common Stock's assets decreased by 61.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Skye Bioscience, Inc. Common Stock (2012–2025)
The table below shows the annual total assets of Skye Bioscience, Inc. Common Stock from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $28.31 Million | -61.09% |
| 2024-12-31 | $72.76 Million | +509.39% |
| 2023-12-31 | $11.94 Million | +31.05% |
| 2022-12-31 | $9.11 Million | -7.55% |
| 2021-12-31 | $9.86 Million | +268.87% |
| 2020-12-31 | $2.67 Million | +33.80% |
| 2019-12-31 | $2.00 Million | +2.02% |
| 2018-12-31 | $1.96 Million | +251.23% |
| 2017-12-31 | $557.22K | +72.32% |
| 2016-12-31 | $323.36K | -90.79% |
| 2015-12-31 | $3.51 Million | +907.92% |
| 2014-12-31 | $348.35K | +139.09% |
| 2013-12-31 | $145.69K | +239.74% |
| 2012-12-31 | $42.88K | -- |
About Skye Bioscience, Inc. Common Stock
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1… Read more